Hims & Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public telehealth company.

First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

Hims Hard Mints are a discreet alternative to erectile dysfunction pills. They’re created by a process called compounding. Compounded medications are customized or altered to meet a specific ...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock of late. Shares of the San Francisco, CA-based health and wellness platform have gained 8.6% in ...

The FDA wants to end bulk production of copycat versions of weight loss drugs; telehealth companies and compounding ...

On the plus side, Hims can save you the hassle of an in-person doctor’s appointment and a trip to the pharmacy. The online process is straightforward, and products ship directly to you.

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Hims & Hers acquired Apostrophe for $190 million ... The company also offers to transfer patients’ prescriptions to a pharmacy of their choice. Apostrophe owned and operated a mail-order ...

Hims & Hers Health is now reasonably valued ... First, Novo Nordisk (NVO) launched its own online pharmacy, NovoCare Pharmacy, and the price of its Wegovy drug was slashed to $499 a month, much ...

Hims & Hers Health (NYSE:HIMS) shares were on a massive run, but that momentum hit a wall recently. Since its peak on February 19, the ...

Hims & Hers has bet big on prescribing compounded versions of these drugs, including by buying its own compounding pharmacy in September. The FDA has allowed pharmacies to make compounded versions ...